The L3S has been awarded funding as a partner in REGolution, a newly approved Marie Skłodowska-Curie Actions Doctoral Network (MSCA-DN) under the Horizon Europe programme. The project, led by Universiteit Utrecht, brings together nine beneficiary institutions from seven European countries and will run for 48 months starting January 2027.
AI Expertise at the Heart of Drug Regulation
REGolution will train 14 doctoral candidates in advanced quantitative methods to support robust regulatory decision-making in drug development. L3S contributes its expertise in machine learning and AI-driven methodologies to develop transparent, interpretable research tools across the medicine lifecycle.
The doctoral candidates will work on methodological innovations for clinical trials, the analysis of real-world data for underrepresented populations, and AI-driven approaches to regulatory and Health Technology Assessment decision-making. All results will be made openly available as software, frameworks, and guidance materials for regulators and the scientific community.
International Consortium, Local Strengths
Alongside L3S, the consortium includes the University Medical Center Göttingen, the Paul-Ehrlich-Institut, the University of Oslo, the University of Copenhagen, Friedrich-Alexander-Universität Erlangen-Nürnberg, and AP-HP Paris Cité, among others. The involvement of both L3S and the University Medical Center Göttingen reflects an established collaboration: both institutions are core partners within CAIMed, the Lower Saxony Center for AI and Causal Methods in Medicine, where the intersection of AI methodology and clinical research is already a shared focus.
